Search

Your search keyword '"Fargnoli MC"' showing total 465 results
Start Over Author "Fargnoli MC"
465 results on '"Fargnoli MC"'

1. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, and Aloisi E

Subjects
psoriasis, secukinumab, real-world evidence, drug survival, supreme, Dermatology, RL1-803
Abstract

Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,† Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Section of Dermatology, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genova, Italy; 14Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 15Section of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 16Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 17Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 18Section of Dermatology, Department of Medical and Surgical Specialties, University of Catania, Catania, Italy; 19Dermatology Clinic of Terni, University of Perugia, Perugia, Italy; 20Section of Dermatology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 21Department of Health Sciences, Magna Graecia University, Catanzaro, Italy; 22Department of Medicine and Surgery, University of Parma, Parma, Italy; 23Section of Dermatology, Department of Biotechnological and Applied Clinical Science, University of L’Aquila, L’Aquila, Italy; 24Department of Dermatology, Istituto Dermopatico dell’Immacolata - IRCCS, Roma, Italy; 25Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Dermatology Unit, “Daniele Innocenzi”, Asl Latina, Italy; 26Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 27Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; 28Dermatology Unit, Lucca Azienda USL Toscana Nord Ovest, Pisa, Italy; 29Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; 30Department of Dermatology, University of Trieste, Trieste, Italy; 31Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 32Department of Dermatology, University of Bari, Bari, Italy; 33Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; 34Dermatology Unit, Vito Fazzi Hospital, Lecce, Italy; 35Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy; 36Dermatology Unit, IRCCS IO Galeazzi, Milan, Italy; 37Dermatological Clinic, Polytechnic University of the Marche Region, Ancona, Italy; 38Department of Dermatology, Istituto Dermatologico San Gallicano - IRCCS, Roma, Italy; 39Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 40Novartis Farma SpA, Origgio, Italy; 41National Centre for Healthcare Research and Pharmacoepidemiology, Milan, Italy; 42Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy†Gabriella Fabbrocini passed away on 3 March 2023Correspondence: Filomena Russo, Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy, Email file.russo@libero.itPurpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings.Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.Keywords: psoriasis, secukinumab, real-world evidence, drug survival, SUPREME

Published
2023

2. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Author

Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fargnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, and Costanzo A

Subjects
psoriasis, biologics, interleukin-17a, secukinumab, elderly, Dermatology, RL1-803
Abstract

Marina Talamonti,1 Filomena Russo,2 Giovanna Malara,3,4 Katharina Hansel,5 Manuela Papini,6 Angelo Cattaneo,7 Aurora Parodi,8 Andrea Chiricozzi,9,10 Piergiorgio Malagoli,11 Federico Bardazzi,12 Valeria Brazzelli,13 Paolo Dapavo,14 Paolo Gisondi,15 Cristina Zane,16 Concetta Potenza,17 Franca Cantoresi,18 Maria Concetta Fargnoli,19 Sara Trevisini,20 Pina Brianti,21 Leonardo Pescitelli,22 Giovanni Gigante,23 Marta Bartezaghi,23 Luisa Caputo,23 Elisabetta Aloisi,23 Antonio Costanzo24,25 On behalf of the SUPREME Study Group1Dermatology, University of Rome Tor Vergata, Rome, Italy; 2Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy; 3Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio, Calabria, Italy; 4Department of Dermatology, Papardo Hospital, Messina, Italy; 5Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 6Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 7U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 8Di.S.Sal. Section of Dermatology, Ospedale Policlinico San Martino, University of Genova, Genova GE, 16132, Italy; 9UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; 10Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; 11Psocare Unit, I.R.C.C.S Policlinico San Donato, Milano, Italy; 12Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 13Dermatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 14Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Torino, Torino, Italy; 15Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; 16Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 17Dermatology Unit “Daniele Innocenzi”, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome – Polo Pontino, Latina, Italy; 18Dermatology Unit, Department of Medicine, University of Roma, Roma, Italy; 19Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 20Department of Dermatology, University of Trieste, Trieste, Italy; 21Dermatology and Cosmetology Unit - San Raffaele Hospital, Milan, Italy; 22Department of Health Sciences, Dermatology Clinic, University of Firenze, Firenze, Italy; 23Novartis Farma SpA, Origgio, Italy; 24Unit of Dermatology, IRCCS Humanitas Research Hospital, Milano, Italy; 25Department of Biomedical Sciences, Humanitas University, Milano, ItalyCorrespondence: Marina Talamonti, Dermatology-Department of Systems Medicine, University of Rome Tor Vergata, PTV – Policlinico Tor Vergata, V.le Oxford 81, Rome, 00133, Italy, Tel +39 0620902743, Fax +39 0620902742, Email talamonti.marina@gmail.comPurpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study.Patients and Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month. We compared the following outcomes in patients aged ≥ 65 years vs < 65 years: baseline characteristics; PASI50/75/90/100 response rates (improvements ≥ 50%/75%/90%/100% in Psoriasis Area and Severity Index (PASI) from baseline); changes in Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Scale (HAD-A, HAD-D) score changes; treatment-emergent adverse events (TEAEs).Results: Secukinumab was slightly less effective in elderly patients than in adult patients (response rates at week 16: PASI90, 69.4% vs 80.9%, p = 0.4528; PASI100, 44.4% vs 56.7%, p = 0.8973). Elderly and adult patients showed a similar time course of changes in absolute PASI scores. Patients aged ≥ 65 years had a statistically significantly lower improvement in quality of life (mean DLQI reduction) than patients aged < 65 years at week 16 [− 5.4 (± 4.3) vs − 8.8 (± 6.9), p = 0.0065] and at week 24 [− 5.3 (± 4.4) vs − 9.2 (± 7.1), p = 0.0038]. Secukinumab treatment resulted in comparable mean reductions in anxiety and depression scores in both cohorts at 24 weeks [HAD-A, − 1.3 (± 3.3) vs − 2.1 (± 3.8), p = 0.9004; HAD-D, − 1.0 (± 3.3) vs − 1.5 (± 3.1), p = 0.4598]. The frequency of TEAEs in the two cohorts was similar (16.7% vs 14.6%, p = 0.7391).Conclusion: Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.Keywords: psoriasis, biologics, interleukin-17A, secukinumab, elderly

Published
2023

3. Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

Author

Argenziano G, Amerio P, Aragone MG, Baggini G, Baldari M, Castelli G, Coppola S, Costanzo A, De Pasquale R, Fargnoli MC, Foti C, Giofrè C, Lembo S, Leporati C, Loconsole F, Malara G, Peris K, Richetta AG, Savoia P, Tiberio R, Travaglini M, Uzzauto MT, and Bianchi L

Subjects
dermatology, psolife care program, quality of life, treatment adherence, Medicine (General), R5-920
Abstract

Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena Lembo,14 Claudia Leporati,15,16 Francesco Loconsole,17 Giovanna Malara,18 Ketty Peris,19,20 Antonio Giovanni Richetta,21 Paola Savoia,22 Rossana Tiberio,23 Massimo Travaglini,24 Maria Teresa Uzzauto,25 Luca Bianchi26,* 1Dermatology Unit, University of Campania, Naples, Italy; 2Department of Medicine and Aging Science and Dermatologic Clinic, University “G. d’Annunzio”, Chieti-Pescara, Chieti, Italy; 3ASL AL, Alessandria, Italy; 4Osp. Civile di Varzi, Pavia, Italy; 5ASL4 Liguria, Genova, Italy; 6UOSD of Dermatology, Ospedale Umberto I°, Siracusa, Italy; 7IQVIA, Rome, Italy; 8Department of Biomedical Sciences, Humanitas University, Milano, Italy; 9Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 10UOC Dermatologia, AOU Policlinico “G. Rodolico – San Marco”, Catania, Italy; 11Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 12Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy; 13U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 14Dipartimento di Medicina, Chirurgia e Odontoiatria Scuola Medica Salernitana, University of Salerno, Fisciano, Italy; 15Dermatology Unit, ASL AL Casale Monferrato, Alessandria, Italy; 16Dermatology Unit, ASL TO4 Ivrea, Torino, Italy; 17Department of Dermatology, University of Bari, Bari, Italy; 18UOC of Dermatology, Grande Ospedale Metropolitano “BMM”, Reggio Calabria, Italy; 19Institute of Dermatology, Catholic University, Rome, Italy; 20Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 21Dipartimento di Scienze Cliniche Internistiche e Cardiovascolari Policlinico Umberto I University of Rome “La Sapienza”, Rome, Italy; 22Department of Health Science, Università del Piemonte Orientale, Novara, Italy; 23SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy; 24U.O.S.D. dermatologica - centro per la cura della psoriasi, Ospedale Perrino, Brindisi, Italy; 25U.O.C. Dermatologia, ASL Salerno, Ospedale “A:Tortora”-Pagani, Salerno, Italy; 26Dermatology Unit, Tor Vergata University Hospital, Rome, Italy*These authors contributed equally to this workCorrespondence: Giuseppe ArgenzianoDermatology Unit, University of Campania “Luigi Vanvitelli”, Via Pansini, 5, Naples, 80131, ItalyTel +39335415093Fax +39 069 762 5822Email g.argenziano@gmail.comLuca BianchiUniversity of Rome “Tor Vergata”, Policlinico Tor Vergata, Viale Oxford 81, Rome, 00133, ItalyTel +39 0620902739Fax +39 0620902742Email luca.bianchi@uniroma2.itPurpose: For patients with psoriasis, treatment adherence and persistence are fundamental if therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support tool to assist patients and health care professionals optimize treatment and improve disease management.Patients and Methods: In Italy, the PSP PSOLife CARE, which began on the 9th of February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with secukinumab (Cosentyx®). A team of medical professionals including Dermatologists, Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote support via phone calls. Patients had a standard duration in the Program of 6 months. This report analyzes the data of patients who benefited from the Program from February 2017 to August 2020, for a total observation of 42 months.Results: We provide here a descriptive report on the benefits of participation in the PSOLife CARE Program for patients with psoriasis and medical professionals involved in their care. Throughout their time in the PSOLife CARE Program, patient satisfaction remained consistently high with sustained improvements observed in all aspects of quality of life (ie emotional, social, physical, and economic). Despite exiting from the Program, most patients continued to adhere to secukinumab. Medical professionals also reported positive outcomes on their interactions with patients, with more than half of those surveyed rating the overall quality of the Program as “Outstanding”.Conclusion: By supporting treatment adherence, the PSOLife CARE Program may have empowered patients to better manage their psoriasis, increasing their satisfaction with treatment and quality of life.Keywords: dermatology, PSOLife CARE Program, quality of life, treatment adherence

Published
2021

4. MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project

Author

Tagliabue E, Gandini S, Bellocco R, Maisonneuve P, Newton-Bishop J, Polsky D, Lazovich D, Kanetsky PA, Ghiorzo P, Gruis NA, Landi MT, Menin C, Fargnoli MC, García-Borrón JC, Han J, Little J, Sera F, and Raimondi S

Subjects
Pooled-analysis, genetic epidemiology, cutaneous melanoma, Melanocortin-1 Receptor, pigmentation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Elena Tagliabue,1 Sara Gandini,2 Rino Bellocco,3,4 Patrick Maisonneuve,2 Julia Newton-Bishop,5 David Polsky,6 DeAnn Lazovich,7 Peter A Kanetsky,8 Paola Ghiorzo,9,10 Nelleke A Gruis,11 Maria Teresa Landi,12 Chiara Menin,13 Maria Concetta Fargnoli,14 Jose Carlos García-Borrón,15,16 Jiali Han,17 Julian Little,18 Francesco Sera,19 Sara Raimondi2 On behalf of the M-SKIP Study Group 1Clinical Trial Center, Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, 2Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 4Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy; 5Section of Epidemiology and Biostatistics, Institute of Cancer and Pathology, University of Leeds, Leeds, UK; 6Ronald O. Perelman Department of Dermatology, New York University School of Medicine, NYU Langone Medical Center, New York, NY, 7Division of Epidemiology and Community Health, University of Minnesota, MN, 8Department of Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 9Department of Internal Medicine and Medical Specialties, University of Genoa, 10IRCCS AOU San Martino-IST, Genoa, Italy; 11Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA; 13Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, 14Department of Dermatology, University of L’Aquila, L’Aquila, Italy; 15Department of Biochemistry, Molecular Biology, and Immunology, University of Murcia, 16IMIB-Arrixaca, Murcia, Spain; 17Department of Epidemiology, Richard M Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA; 18School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; 19Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, UK Purpose: Melanoma represents an important public health problem, due to its high case-fatality rate. Identification of individuals at high risk would be of major interest to improve early diagnosis and ultimately survival. The aim of this study was to evaluate whether MC1R variants predicted melanoma risk independently of at-risk phenotypic characteristics. Materials and methods: Data were collected within an international collaboration – the M-SKIP project. The present pooled analysis included data on 3,830 single, primary, sporadic, cutaneous melanoma cases and 2,619 controls from seven previously published case–control studies. All the studies had information on MC1R gene variants by sequencing analysis and on hair color, skin phototype, and freckles, ie, the phenotypic characteristics used to define the red hair phenotype. Results: The presence of any MC1R variant was associated with melanoma risk independently of phenotypic characteristics (OR 1.60; 95% CI 1.36–1.88). Inclusion of MC1R variants in a risk prediction model increased melanoma predictive accuracy (area under the receiver-operating characteristic curve) by 0.7% over a base clinical model (P=0.002), and 24% of participants were better assessed (net reclassification index 95% CI 20%–30%). Subgroup analysis suggested a possibly stronger role of MC1R in melanoma prediction for participants without the red hair phenotype (net reclassification index: 28%) compared to paler skinned participants (15%). Conclusion: The authors suggest that measuring the MC1R genotype might result in a benefit for melanoma prediction. The results could be a valid starting point to guide the development of scientific protocols assessing melanoma risk prediction tools incorporating the MC1R genotype. Keywords: pooled analysis, genetic epidemiology, cutaneous melanoma, melanocortin 1 receptor, pigmentation

Published
2018

5. Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia

Author

Dalmasso, B, Pastorino, L, Nathan, V, Shah, NN, Palmer, JM, Howlie, M, Johansson, PA, Freedman, ND, Carter, BD, Beane-Freeman, L, Hicks, B, Molven, A, Helgadottir, H, Sankar, A, Tsao, H, Stratigos, AJ, Helsing, P, Van Doorn, R, Gruis, NA, Visser, M, Wadt, KAW, Mann, G, Holland, EA, Nagore, E, Potrony, M, Puig, S, Menin, C, Peris, K, Fargnoli, MC, Calista, D, Soufir, N, Harland, M, Bishop, T, Kanetsky, PA, Elder, DE, Andreotti, V, Vanni, I, Bruno, W, Höiom, V, Tucker, MA, Yang, XR, Andresen, PA, Adams, DJ, Landi, MT, Hayward, NK, Goldstein, AM, and Ghiorzo, P

Subjects
Genetics, Human Genome, Cancer, 2.1 Biological and endogenous factors, Aetiology, Ataxia Telangiectasia, Ataxia Telangiectasia Mutated Proteins, Australia, Genetic Predisposition to Disease, Germ-Line Mutation, Humans, Melanoma, GenoMEL, MelaNostrum consortia, Clinical Sciences, Genetics & Heredity
Abstract

PurposeAtaxia-Telangiectasia Mutated (ATM) has been implicated in the risk of several cancers, but establishing a causal relationship is often challenging. Although ATM single-nucleotide polymorphisms have been linked to melanoma, few functional alleles have been identified. Therefore, ATM impact on melanoma predisposition is unclear.MethodsFrom 22 American, Australian, and European sites, we collected 2,104 familial, multiple primary (MPM), and sporadic melanoma cases who underwent ATM genotyping via panel, exome, or genome sequencing, and compared the allele frequency (AF) of selected ATM variants classified as loss-of-function (LOF) and variants of uncertain significance (VUS) between this cohort and the gnomAD non-Finnish European (NFE) data set.ResultsLOF variants were more represented in our study cohort than in gnomAD NFE, both in all (AF = 0.005 and 0.002, OR = 2.6, 95% CI = 1.56-4.11, p

Published
2021

6. Profilo super responder in corso di trattamento con bimekizumab: studio retrospettivo multicentrico nella psoriasi moderato-grave

Author

Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, Richetta, AG, Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, and Richetta, AG

Abstract

Bimekizumab è un anticorpo monoclonale umanizzato, recentemente approvato per il trattamento della psoriasi a placche moderato-grave, inibitore selettivo delle isoforme dell’interleuchina-17A e F. Le esperienze real-life riguardanti l’utilizzo del farmaco sono limitate ed il profilo del paziente con riposta più elevata PASI100 cioè super responder SR non è stato analizzato. Presentiamo questo studio multicentrico, retrospettivo volto a disegnare il profilo del paziente che beneficia maggiormente del trattamento con bimekizumab, considerando come SR coloro che raggiungono PASI 100 alla settimana-4 e 16. Sono stati studiati pazienti adulti affetti da psoriasi moderato-grave, trattati con bimekizumab per almeno 16 settimane presso 21 centri dermatologici italiani, secondo regole di appropriatezza AIFA e in accordo con la scheda tecnica del farmaco. Endpoints di efficacia erano PASI75, PASI90 e PASI100 alla settimana 4 e 16, ed in particolare la percentuale di SR ai due tempi. I pazienti che non raggiungevano tale target venivano definiti come non-super responders NSRs. Sono stati studiati 137 pazienti con età media 52,47±15,56 anni, BMI medio 27,43±5,91 e PASI medio al basale di 16,00±9,29. Alla settimana 4 il 72% dei pazienti raggiungeva PASI75, il 50% PASI90, mentre il 43% otteneva PASI100, definendo la popolazione SR alla settimana 4. Alla settimana 16, il 93% dei pazienti raggiungeva PASI75, il 77% PASI90, il 70% dei pazienti risultava essere SR mentre solo il 7% non raggiungeva PASI 75. Sono emerse alcune differenze caratterizzanti pazienti con un più rapido raggiungimento dello stato di SRs alla settimana 4 rispetto alla settimana 16: età ≥46<65, coesistenza di <2 comorbidità e stato naïve a precedenti trattamenti biologici. Considerando alcune caratteristiche clinico-demografiche è stata condotta un’analisi univariata per valutare le differenze tra SR e NSRs. Lo stato di NSR è risultato associato significativamente alla settimana 4 con: BMI≥25 &

Published
2024

9. Corrigendum to 'Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma' [Eur J Canc 157 (2021) 250-258]

Author

Baggi, A, Quaglino, P, Rubatto, M, Depenni, R, Guida, M, Ascierto, Pa, Trojaniello, C, Queirolo, P, Saponara, M, Peris, K, Spagnolo, F, Bianchi, L, De Galitiis, F, Potenza, Mc, Proietti, I, Marconcini, R, Botticelli, A, Barbieri, V, Licitra, L, Alfieri, S, Ficorella, C, Cortellini, A, Fargnoli, Mc, Troiani, T, Tondulli, L, Zamparini, M, and Bossi, P

Subjects
Cancer Research, Settore MED/35, Oncology
Published
2022

10. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Author

Griffiths, C, de Bruin-Weller, M, Deleuran, M, Fargnoli, MC, Staumont-Salle, D, Hong, C-H, Sanchez-Carazo, J, Foley, P, Seo, SJ, Msihid, J, Chen, Z, Cyr, SL, Rossi, AB, Griffiths, C, de Bruin-Weller, M, Deleuran, M, Fargnoli, MC, Staumont-Salle, D, Hong, C-H, Sanchez-Carazo, J, Foley, P, Seo, SJ, Msihid, J, Chen, Z, Cyr, SL, and Rossi, AB

Abstract

INTRODUCTION: Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit-risk profile. However, systemic non-steroidal immunosuppressants (NSISS) are often used as first-line therapy in clinical practice. Impact of prior therapy with NSISS on dupilumab's treatment effect vs. control has not been described previously. This study assessed dupilumab's efficacy vs. control in patients with moderate-to-severe AD, comparing treatment effect in patients with/without prior systemic NSISS therapy, in four phase 3 trials. METHODS: This post hoc analysis included 1553 patients randomized to placebo or dupilumab (300 mg q2w) as monotherapy for 16 weeks, or with concomitant topical corticosteroids (TCS) for 16/52 weeks, from four randomized, double-blind, placebo-controlled, phase 3 trials. Patients were stratified by prior use of systemic NSISS and dupilumab-treated patients were analysed against control groups (treated with placebo or placebo + TCS). RESULTS: Dupilumab-treated patients, regardless of prior treatment with NSISS, achieved a significantly higher percentage reduction from baseline in Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Dermatology life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM) vs. control; significantly more achieved EASI score ≤ 7, Peak Pruritus Numerical Rating Scale ≤ 4, POEM ≤ 7, and DLQI ≤ 5 by week 4. These rapid, significant improvements were seen with or without concomitant TCS and sustained through end-of-treatment. CONCLUSIONS: Dupilumab treatment (monotherapy or + TCS) provides rapid, significant, sustained improvements in signs, symptoms, and quality of life in patients with moderate-to-severe AD compared with control, regardless of prior systemic NSISS use. CLINICAL TRIAL REGISTRATION: LIBERTY AD SOLO 1: ClinicalTrials.gov identifier NCT02277743, EudraCT 2014-001198-15.

Published
2021

11. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

Author

Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo A, Bianchi L, Bottoni U, Buligan C, Brazzelli V, Campanati A, Cantoresi F, Capo A, Cattaneo A, Dapavo P, Del Giglio M, Di Lernia V, Di Nuzzo S, De Simone C, Dusi D, Fargnoli MC, Flori ML, Franchi C, Galluzzo M, Ghilardi A, Hansel K, Loconsole F, Lora V, Malagoli P, Malara G, Mastrandrea V, Megna M, Mercuri SR, Musumeci ML, Naldi L, Narcisi A, Orsini D, Pagnanelli G, Patrizi A, Pau M, Pellacani G, Persechino S, Piaserico S, Pietroleonardo L, Prignano F, Reseghetti A, Russo F, Sirna R, Skroza N, Stingeni L, Trevisini S, Zane C, Zichichi L, Zini A., Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo, A, Bianchi, L, Bottoni, U, Buligan, C, Brazzelli, V, Campanati, A, Cantoresi, F, Capo, A, Cattaneo, A, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, De Simone, C, Dusi, D, Fargnoli, Mc, Flori, Ml, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Malara, G, Mastrandrea, V, Megna, M, Mercuri, Sr, Musumeci, Ml, Naldi, L, Narcisi, A, Orsini, D, Pagnanelli, G, Patrizi, A, Pau, M, Pellacani, G, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Russo, F, Sirna, R, Skroza, N, Stingeni, L, Trevisini, S, Zane, C, Zichichi, L, and Zini, A.

Subjects
Moderate to severe, medicine.medical_specialty, business.industry, secukinumab, HLA-Cw6, Dermatology, Plaque type psoriasis, moderate-to-severe plaque-type psoriasis, Clinical trial, Severity of illness, Monoclonal, Medicine, In patient, Secukinumab, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Prospective cohort study
Abstract

Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. The Phase 3b SUPREME study (NCT02394561) demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque-type psoriasis, irrespective of HLA-Cw6 status at week 24. This article is protected by copyright. All rights reserved.

Published
2019

12. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

Author

Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Debniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hocevar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubinski J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novakovic S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA, GenoMEL Consortium, Q-MEGA and QTWIN Investigators, ATHENS Melanoma Study Group, 23andMe, SDH Study Group, IBD Investigators, Essen-Heidelberg Investigators, AMFS Investigators, MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, and Law MH

Abstract

Meta-analysis of 36,760 cases and 375,188 controls identifies 54 loci associated with susceptibility to cutaneous melanoma. Further analysis combining nevus count and hair color GWAS results provide insights into the genetic architecture of melanoma. Most genetic susceptibility to cutaneous melanoma remains to be discovered. Meta-analysis genome-wide association study (GWAS) of 36,760 cases of melanoma (67% newly genotyped) and 375,188 controls identified 54 significant (P < 5 x 10(-8)) loci with 68 independent single nucleotide polymorphisms. Analysis of risk estimates across geographical regions and host factors suggests the acral melanoma subtype is uniquely unrelated to pigmentation. Combining this meta-analysis with GWAS of nevus count and hair color, and transcriptome association approaches, uncovered 31 potential secondary loci for a total of 85 cutaneous melanoma susceptibility loci. These findings provide insights into cutaneous melanoma genetic architecture, reinforcing the importance of nevogenesis, pigmentation and telomere maintenance, together with identifying potential new pathways for cutaneous melanoma pathogenesis.

Published
2020

13. Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life

Author

Caldarola, G, De Simone, C, Talamonti, M, Moretta, G, Fossati, B, Bianchi, L, Fargnoli, Mc, and Peris, K

Subjects
Adult, Male, comorbidities, psoriasis, quality of life, skin diseases, Comorbidity, psoriatic patients, cutaneous comorbidities, Middle Aged, Dermatitis, Contact, Dermatitis, Seborrheic, Dermatitis, Atopic, Italy, Acne Vulgaris, Rosacea, Prevalence, Quality of Life, Humans, Psoriasis, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE
Abstract

In contrast to the evidence for systemic co-morbidities, relatively few studies have examined the prevalence of cutaneous inflammatory co-morbidities in psoriatic patients. We conducted an observational multi-site study to measure the prevalence of cutaneous co-morbidities in adult patients with plaque psoriasis and to assess the relative impact on quality of life (QOL). Each patient attending one of the study clinics over a period of six months was evaluated to assess the presence of any concomitant skin inflammatory disease other than psoriasis at the time of the visit. Patients were also asked to complete QOL surveys at the initial visit, using DLQI, SF36, Skindex 29, and PDI. A total of 118 study participants (21.1%) had a cutaneous comorbidity. The most common cutaneous co-morbidities were rosacea (23 cases; 4.1%) and acne vulgaris (22 cases; 3.9%). Psoriatic patients with co-existing skin diseases had a worse QOL than those without, as evidenced by DLQI, Skindex 29, and PDI scores. Dermatologists should take a global approach to manage psoriatic patients by carefully evaluating the skin for any disorder and providing treatment to achieve "clean" skin.

Published
2019

14. Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life.

Author

Caldarola, Giacomo, De Simone, Clara, Talamonti, M, Moretta, G, Fossati, Barbara, Bianchi, L, Fargnoli, Mc, Peris, Ketty, Caldarola G (ORCID:0000-0002-8837-9232), De Simone C (ORCID:0000-0002-0898-0045), Fossati B, Peris K. (ORCID:0000-0002-5237-0463), Caldarola, Giacomo, De Simone, Clara, Talamonti, M, Moretta, G, Fossati, Barbara, Bianchi, L, Fargnoli, Mc, Peris, Ketty, Caldarola G (ORCID:0000-0002-8837-9232), De Simone C (ORCID:0000-0002-0898-0045), Fossati B, and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

In contrast to the evidence for systemic co-morbidities, relatively few studies have examined the prevalence of cutaneous inflammatory co-morbidities in psoriatic patients. We conducted an observational multi-site study to measure the prevalence of cutaneous co-morbidities in adult patients with plaque psoriasis and to assess the relative impact on quality of life (QOL). Each patient attending one of the study clinics over a period of six months was evaluated to assess the presence of any concomitant skin inflammatory disease other than psoriasis at the time of the visit. Patients were also asked to complete QOL surveys at the initial visit, using DLQI, SF36, Skindex 29, and PDI. A total of 118 study participants (21.1%) had a cutaneous comorbidity. The most common cutaneous co-morbidities were rosacea (23 cases; 4.1%) and acne vulgaris (22 cases; 3.9%). Psoriatic patients with co-existing skin diseases had a worse QOL than those without, as evidenced by DLQI, Skindex 29, and PDI scores. Dermatologists should take a global approach to manage psoriatic patients by carefully evaluating the skin for any disorder and providing treatment to achieve "clean" skin.

Published
2019

15. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Author

Peris, K, Fargnoli, Mc, Garbe, C, Kaufmann, R, Bastholt, L, Seguin, Nb, Bataille, V, Marmol, Vd, Dummer, R, Harwood, Ca, Hauschild, A, Höller, C, Haedersdal, M, Malvehy, J, Middleton, Mr, Morton, Ca, Nagore, E, Stratigos, Aj, Szeimies, Rm, Tagliaferri, L, Trakatelli, M, Zalaudek, I, Eggermont, A, Grob, Jj, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)., Peris K (ORCID:0000-0002-5237-0463), Tagliaferri L (ORCID:0000-0003-2308-0982), Zalaudek I, Peris, K, Fargnoli, Mc, Garbe, C, Kaufmann, R, Bastholt, L, Seguin, Nb, Bataille, V, Marmol, Vd, Dummer, R, Harwood, Ca, Hauschild, A, Höller, C, Haedersdal, M, Malvehy, J, Middleton, Mr, Morton, Ca, Nagore, E, Stratigos, Aj, Szeimies, Rm, Tagliaferri, L, Trakatelli, M, Zalaudek, I, Eggermont, A, Grob, Jj, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)., Peris K (ORCID:0000-0002-5237-0463), Tagliaferri L (ORCID:0000-0003-2308-0982), and Zalaudek I

Abstract

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC. A new classification into 'easy-to-treat (common) BCC and 'difficult-to-treat' BCC is proposed. Diagnosis is based on clinicodermatoscopic features for 'easy-to-treat' BCCs. Histopathological confirmation is mandatory in ambiguous lesions and in BCCs located in high-risk areas. The first-line treatment of 'easy-to-treat' BCC is complete surgery. Microscopically controlled surgery shall be offered for high-risk BCC, recurrent BCC and BCC in critical anatomical sites. Topical therapies (5% imiquimod, 5% fluorouracil) and destructive approaches (curettage, electrocautery, cryotherapy, laser ablation) should be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial BCC and thin nodular BCC. The therapy for a 'difficult-to-treat' BCC should preferentially be discussed by a multidisciplinary tumour board. Hedgehog inhibitors, vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCCs. Immunotherapy with anti-programmed cell death 1 (PD-1) antibodies is a promising therapeutic option, currently being investigated in clinical trials. Radiotherapy represents a valid alternative to surgery for BCC on the face, especially in elderly patients. In patients with naevoid basal cell carcinoma syndrome (NBCCS), close surveillance and regular skin examinations are required to diagnose and treat BCCs at early stage. Long-term follow-up is recommended in patients with high-risk BCC subtypes, high-risk sites, multiple BCCs and NBCCS.

Published
2019

16. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. SUPREME study

Author

Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Bottoni, U, Brazzelli, V, Burlando, M, Cantoresi, F, Capo, A, Cattaneo, A, Cusano, F, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, Dusi, D, Fargnoli, Mc, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Mastrandrea, V, Megna, M, Mercuri, Sr, Letizia Musumeci, M, Naldi, L, Narcisi, A, Offidani, A, Pagnanelli, G, Papini, M, Patrizi, A, Pau, M, Pellacani, G, Peris, K, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Romanelli, M, Russo, F, Sirna, R, Skroza, N, Stinco, G, Trevisini, S, Zane, C, Zichichi, L, Zini, A., Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Persechino, Severino, Pau, Monica, Cusano, Francesco, Russo, Filomena, Stinco, Giuseppe, Ghilardi, Alberto, Del Giglio, Micol, De Luca, Giuseppe, Brazzelli, Valeria, Fargnoli, Maria Concetta, Capo, Alessandra, Mastrandrea, Valentina, Piaserico, Stefano, Franchi, Chiara, Zane, Cristina, Cattaneo, Angelo, Galluzzo, Marco, La Selva, Roberta, Di Nuzzo, Sergio, Megna, Matteo, Pellacani, Giovanni, Peris, Ketty, Patrizi, Annalisa, Trevisini, Sara, Pagnanelli, Gianluca, Skroza, Nevena, Malagoli, Piergiorgio, Resghetti, Alberto, Burlando, Martina, Loconsole, Francesco, Offidani, Anna Maria, Albertini, Giuseppe, Mercuri, Santo Raffaele, Bottoni, Ugo, Dusi, Daniele, Zini, Antonio, Pietroleonardo, Lucia, Cantoresi, Franca, Sirna, Riccardo, Lora, Viviana, Hansel, Katharina, Prignano, Francesca, and Natalini, Ylenia

Subjects
Adult, Male, medicine.medical_specialty, Psoriasis, secukinumab, Genotyping Techniques, Dermatology, HLA-C Antigens, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Antibodies, Monoclonal, Biomarkers, Female, Genetic Predisposition to Disease, Humans, Interleukin-17, Italy, Middle Aged, Prospective Studies, Psoriasis, Treatment Outcome, 0302 clinical medicine, Internal medicine, Severity of illness, Monoclonal, medicine, Clinical endpoint, Adverse effect, Prospective cohort study, Humanized, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, medicine.disease, Confidence interval, 030220 oncology & carcinogenesis, Secukinumab, Interleukin 17, business
Abstract

Background Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. Objectives To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis. Methods SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks. Results In total, 434 patients were recruited: 185 (42·6%) were Cw6-POS and 246 (56·7%) were Cw6-NEG (three not assessed). Mean ± SD age was 45·2 ± 13·2 years (Cw6-POS 42·7 ± 13·1; Cw6-NEG 47·2 ± 12·9). The baseline PASI score was comparable between the cohorts [Cw6-POS 20·7 ± 8·99; Cw6-NEG 21·5 ± 9·99 (P = 0·777)]. At week 16, PASI 90 was achieved in 80·4% of Cw6-POS and 79·7% of Cw6-NEG patients (difference 0·76; 95% confidence interval -7·04 to 8·23). No differences in absolute PASI at week 16 (Cw6-POS 1·36 ± 3·58; Cw6-NEG 1·18 ± 2·29) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42·7%; Cw6-NEG 49·6% (P = 0·295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI. Conclusions Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status.

Published
2018

17. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series

Author

Tambone, S, Fargnoli, Mc, Capizzi, R, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Tambone, S, Fargnoli, Mc, Capizzi, R, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.

Published
2018

18. The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns

Author

BONGIORNO, Maria Rita, Suppa, M, Altomare, G, Cannavò, SP, Capizzi, R, Catricalà, C, Colombo, E, Fargnoli, MC, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, M, Peris, K, Italian investigators for the Euromelanoma prevention campaign, Suppa, M, Altomare, G, Cannavò, Sp, Capizzi, R, Catricalà, C, Colombo, E, Fargnoli, Mc, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, Massimiliano, Peris, K, Italian investigators for the Euromelanoma prevention, c. a. m. p. a. i. g. n., Bongiorno, MR, Cannavò, SP, Fargnoli, MC, Scalvenzi, M, and Italian investigators for the Euromelanoma prevention campaign.

Subjects
Male, Questionnaires, Pediatrics, Skin Neoplasms, Health Behavior, Surveys and Questionnaires, inglese, 80 and over, Settore MED/35 - Malattie Cutanee E Veneree, Mass Screening, Medicine, Skin cancer, Young adult, Child, Melanoma, Early Detection of Cancer, Aged, 80 and over, integumentary system, Incidence (epidemiology), Middle Aged, Day screening campaign, Predictive value, Europe, Italy, Child, Preschool, Sunlight, Female, Risk assessment, Cutaneous malignant melanoma, Adult, medicine.medical_specialty, Adolescent, Dermoscopy, Health Promotion, Dermatology, Risk Assessment, Young Adult, Humans, Preschool, Mass screening, Aged, business.industry, medicine.disease, Surgery, Melanoma detection, Anniversaries and Special Events, Health promotion, business, Program Evaluation
Abstract

Background Melanoma incidence/mortality is increasing worldwide. “Euromelanoma Day” is a pan-European campaign for skin cancer prevention. Results of the 2010 Euromelanoma Day in Italy are reported herein. Materials and methods A questionnaire was used to collect data on participants' characteristics and suspected skin cancers. Result A total of 1085 participants was screened (64.1% females, median age 44 years). Suspicion rate, detection rate, and positive predictive values for melanoma were 1.3, 0.28 and 21.4%, respectively. Poorly educated, ≥35 years old, pale-skinned males were at higher risk for skin cancer than highly educated

Published
2014

20. Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

Author

Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, Griseta V, Psocare Study Group., Miracapillo, A, Azzini, M, Mocci, L, Michelini, M, Offidani, A, Bernardini, L, Campanati, A, Ricotti, G, Giacchetti, Alessandro, Norat, M, Gualco, F, Castelli, A, Cuccia, A, Diana, A, Roncarolo, G, Belli, Ma, Baldassarre, Ma, Santoro, G, Vena, Ga, Lo Console, F, Filotico, R, Mastrandrea, V, Brunetti, B, Musumeci, F, Carrabba, E, Dal Mas, P, Annicchiarico, F, Benvegnù, B, Spaziani, G, Cusano, F, Saletta Iannazzone, S, Galluccio, A, Pezza, M, Marchesi, L, Imberti, G, Reseghetti, A, Barbera, Claudia, Reggiani, Matteo, Lanzoni, A, Patrizi, A, Bardazzi, F, Antonucci, A, De Tommaso, S, Balestri, R, Wallnofer, W, Ingannamorte, F, Calzavara-Pinton, P, Iannazzi, S, Zane, C, Capezzera, R, Bassisi, S, Rossi, Mt, Altamura, V, Vigl, W, SCHETTINO NOBILE, Carla, Aste, N, Murgia, S, Mugheddu, C, Scuderi, G, Baglieri, F, Di Dio, C, Cilioni Grilli, E, Mastronardi, C, Agnusdei, Cp, Antrilli, A, Aulisa, L, Raimondo, U, Scotto di Luzio, G, Battarra, Vc, Farro, P, Plaitano, R, Micali, G, Musumeci, Ml, D'Armiento, Massimino, Li Calzi, M, LA GRECA, SEBASTIANO VITTORIO, Pettinato, Cristiana Maria, Sapienza, G, Valenti, G, De Giacomo PF, D'Amico, D, Arcangeli, Federica, Brunelli, D, Ghetti, E, Tulli, Augusta, Assi, G, Amerio, P, Laria, G, Prestinari, F, Spadafora, S, Coppola, M, Caresana, G, Pezzarossa, E, Domaneschi, E, Felisi, C, Donato, L, Bertero, M, Musso, L, Pa Lazzini, S, Bruscino, P, Agozzino, Uc, Ottaviani, M, Simoncini, Cristiana, Virgili, A, Osti, F, Fabbri, P, Volpi, Walter, Caproni, M, Lotti, T, Prignano, F, Buggiani, G, Troiano, M, Fenizi, G, Altobella, A, Amoruso, A, Condello, M, Goffredo, A, Righini, Mg, Alessandrini, F, Satolli, F, Zampetti, M, Bertani, E, Fossati, S, Parodi, A, Burlando, M, Fiorucci, C, Nigro, A, Ghigliotti, G, Massone, L, Moise, Gm, Serrai, M, Cannata, G, Campagnoli, Am, Daly, M, Leporati, C, Peila, R, Filosa, Giovanna, Bugatti, L, Nicolini, M, Nazzari, G, Cestari, R, Anastasio, Fabio, Larussa, Fm, Pollice, N, De Francesco, F, Mazzocchetti, G, Peris, K, Fargnoli, Mc, Di Cesare, A, De Angelis, L, Flati, G, Biamonte, As, Quarta, Giovanni, Congedo, M, Carcaterra, A, Strippoli, D, Fideli, D, Marsili, Filippo, Celli, M, Ceccarini, M, Bachini, L, D ORIA, MARIA FEDERICA, Schirripa, V, De Filippi, C, Martini, P, Lapucci, E, Mazzatenta, C, Ghilardi, A, Simonacci, M, Bettacchi, A, Gasco, R, Zanca, A, Battistini, Simone, Dattola, S, Vernaci, R, Postorino, F, Zampieri, Pf, Padovan, MARIA CRISTINA, González Intchaurraga MA, Ladurner, J, Guarneri, B, Cannavo', Serena, Manfrè, C, Borgia, F, Puglisi Guerra, A, Sedona, P, Cattaneo, A, Carrera, C, Fracchiolla, C, Mozzanica, N, Prezzemolo, L, Menni, S, Lodi, A, Martino, P, Monti, M, Mancini, L, Sacrini, F, Altomare, Gf, Taglioni, M, Lovati, C, Mercuri, Sr, Schiesari, G, Giannetti, A, Conti, A, Lasagni, C, Greco, M, Ronsini, G, Schianchi, S, Fiorentini, C, Niglietta, S, Miglietta, R, Padalino, C, Crippa, D, Pini, M, Rossi, E, Tosi, D, Armas, M, Ruocco, V, Ayala, F, Balato, N, Gaudiello, F, Cimmino, Gf, Monfrecola, G, Gallo, L, Argenziano, G, Fulgione, E, Berruti, G, Mozzillo, R, Ceparano, S, De Michele, I, Giorgiano, D, Leigheb, G, Deledda, S, Peserico, A, Alaibac, M, Piaserico, S, Schiesari, L, Dan, G, Mattei, I, Oro, E, Aricò, M, Bongiorno, Mr, Angileri, Rosalia, Amato, S, Todaro, F, Milioto, M, Bellastro, R, Di Nuzzo, S, De Panfilis, G, Zanni, M, Borroni, G, Cananzi, R, Brazzelli, V, Lisi, P, Stingeni, L, Hansel, K, Pierfelice, V, Donelli, S, Rastelli, D, Gasperini, M, Barachini, P, Cecchi, R, Bartoli, L, Pavesi, Maria Gabriella, De Paola, S, Corradin, Mt, Ricciuti, F, Piccirillo, Alessandro, Viola, L, Tataranni, M, Mautone, Mg, Lo Scocco, G, Niccoli, Mc, Brunasso Vernetti AM, Gaddoni, G, DI RESTA, Fabio, Casadio, Mc, Arcidiaco, Mc, Luvarà, Mc, ALBERTINI PETRONI, Guglielmo, DI LERNIA, Valerio, Guareschi, E, Catrani, S, Morri, M, De Simone, C, D'Agostino, M, Agostino, I, Calvieri, S, Cantoresi, F, Richetta, A, Sorgi, Paola, Carnevale, C, Nicolucci, F, Berardesca, E, Ardigò, M, De Felice, C, Gubinelli, E, Talamonti, Marina, Camplone, G, Cruciani, Giulio, Riccardi, F, Barbati, R, Zumiani, G, Pagani, W, Malagoli, Pg, Pellicano, R, Donadio, Diego, Di Vito, C, Cottoni, F, Montesu, Ma, Pirodda, C, Addis, G, Marongiu, P, Farris, A, Cacciapuoti, Anna Maria, Verrini, A, Desirello, G, Gnone, M, Fimiani, M, Pellegrino, M, Castelli, G, Zappalà, L, Sesana, G, Ingordo, V, Vozza, E, Di Giuseppe, D, Fasciocco, D, Nespoli, P, Papini, M, Cicoletti, M, Bernengo, Mg, Ortoncelli, M, Bonvicino, A, Capella, G, Doveil, Gc, Forte, M, Peroni, A, Salomone, B, Savoia, P, Pippione, M, Zichichi, Ludovica, Frazzitta, M, De Luca, G, Tasin, L, Simonetto, D, Ros, S, Trevisan, G, Patamia, M, Miertusova, S, Patrone, Pietro, Frattasio, A, Piccirillo, Fabiola, La Spina, S, Di Gaetano, L, Marzocchi, V, Motolese, A, Venturi, Caterina, Gai, Francesco, Pasquinucci, S, Bellazzi, Rm, Silvestri, Tommaso, Veller Fornasa, C, Trevisan, Gp., Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, the Psocare Study Group [.., Annalisa Patrizi, ], Trevisan, Giusto, Girolomoni, G., Maccarone, Sergio, Naldi, L., Gisondi, P., Cazzaniga, S., Chimenti, S., Maccarone, M., Picardo, M., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M.A., Baldassarre, M.A., Santoro, G., Vena, G.A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnù, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M.T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C.P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto Di Luzio, G., Battarra, V.C., Farro, P., Plaitano, R., Micali, G., Musumeci, M.L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P.F., D'Amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa Lazzini, S., Bruscino, P., Agozzino, U.C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M.G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G.M., Serrai, M., Cannata, G., Campagnoli, A.M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F.M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M.C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A.S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P.F., Padovan, C., González Intchaurraga, M.A., Ladurner, J., Guarneri, B., Cannavò, S.P., Manfrè, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G.F., Taglioni, M., Lovati, C., Mercuri, S.R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G.F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Mozzillo, R., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricò, M., Bongiorno, M.R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M.T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M.G., Lo Scocco, G., Niccoli, M.C., Brunasso Vernetti, A.M.G., Gaddoni, G., Resta, F., Casadio, M.C., Arcidiaco, M.C., Luvarà, M.C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigò, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P.G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M.A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalà, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M.G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G.C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R.M., Silvestri, T., Veller Fornasa, C., and Trevisan, G.P.

Subjects
Registrie, Male, taiwan, Antitubercular Agents, Biological Factor, quantiferon-tb-gold, Antitubercular Agent, Biological Factors, experience, Residence Characteristics, 80 and over, Prevalence, Registries, Young adult, risk, Aged, 80 and over, Latent Tuberculosi, Latent tuberculosis, psoriasis, Middle Aged, Italy, Female, tubercolosis, tubercolosi, Adolescent, Adult, Age Distribution, Aged, Chronic Disease, Humans, Latent Tuberculosis, PUVA Therapy, Psoriasis, Sex Distribution, Tuberculin Test, Young Adult, 2708, Human, medicine.drug, medicine.medical_specialty, chronic plaque psoriasis, Tuberculin, consensus statement, Dermatology, tuberculosis infection, Settore MED/35, Internal medicine, medicine, Adalimumab, factor antagonists, necrosis-factor blockers, systemic treatment, therapy, assay, Psoriasi, History of tuberculosis, tuberculosis infection, chronic plaque psoriasis,Italian Psocare Registry, business.industry, Odds ratio, medicine.disease, bacterial infections and mycoses, Confidence interval, Surgery, Residence Characteristic, Italian Psocare Registry, business
Abstract

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8·3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4·3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen–ultraviolet A (P

Published
2015

21. Role of MC1R variants in childhood and adolescent melanoma

Author

Raimondi R, Gandini S, Kanetsky PA, Hoiom V, Kumar R, Ghiorzo P, Debniak T, de Misa RF, Palmieri G, Han J, Landi MT, Dwyer T, Fargnoli MC, Branicki W, Nelleke A. Gruis NA, Stratigos A, Ribas G, Council ML, Kayser M, Autier P, García-Borrón JC, Little J, Newton-Bishop J, Sera F, and Nagore E

Subjects
suscettibilità genetica, MC1R, Melanoma
Abstract

Cutaneous melanoma (CM) is rare in children, representing 1-3% of all paediatric malignancies and occurring at a frequency of 0.3-0.4% before puberty. MC1R is a key gene for skin pigmentation and is highly polymorphic in Caucasians. MC1R gene variants are associated with CM in different populations, and with congenital melanocytic naevi in children. The aim of this study is to evaluate whether the prevalence of MC1R variants differed among sporadic childhood and adolescent CM cases compared to adult patients. Data were gathered through the M-SKIP project, an international pooled-analysis on MC1R variants, skin cancer and phenotypic characteristics. CM cases with information on age at diagnosis were selected from the M-SKIP dataset and divided into three groups: childhood (age 18 years, N=7,696). The frequency of carrying specific MC1R variants as well as at least one MC1R variant were compared between childhood/adolescent and adult CM cases with Chi Square test. The prevalence of any MC1R variant was lower in children (18 years, 75%), although overall the difference was not statistically significant. A higher prevalence of the MC1R V92M variant was found in childhood and adolescent compared to adult CM cases (23% vs 5%, p=0.06). In contrast, the MC1R R151C variant was found less frequently in childhood and adolescent than in adult cases (9% vs 18%, p=0.06). Looking at rare variants in 5,983 cases with MC1R sequenced, 3 (9%) carriers of MC1R ins86A were found among 32 childhood and adolescent patients, while only 44 (1%) carriers of the same variant were found among 5,951 adult cases (p

Published
2015

23. Basi scientifiche per la definizione di linee-guida in ambito clinico per il Melanoma cutaneo

Author

Rossi Cr, Silvestrini R, Ascierto P, Bianchi Scarra' G, Borgognoni L, Chiarion Sileni V, Corti L, De Giorgi V, De Gobbi R, Di Filippo F, Maio M, Massi D, Mocellin S, Mottolese M, Mozzillo N, Palmieri G, Queirolo P, Rivoltini L, Schiavon M, Stanganelli I, Talamini R, Testori A, Caracò C, Pasquali S, Visca P, Bajetta E, Bernengo Mg, Bono R, Botti G, Cascinelli N, Catricala’ C, Chiarugi A, Clemente C, Crocetti E, Fargnoli Mc, Ferraresi V, Gandini S, Ghiorzo P, Guida M, Natali Pg, Parmiani G, Pizzichetta Ma, Ridolfi R, Santinami M, Zanovello P, Rossi, Cr, Silvestrini, R, Ascierto, P, Bianchi Scarra', G, Borgognoni, L, Chiarion Sileni, V, Corti, L, De Giorgi, V, De Gobbi, R, Di Filippo, F, Maio, M, Massi, D, Mocellin, S, Mottolese, M, Mozzillo, N, Palmieri, G, Queirolo, P, Rivoltini, L, Schiavon, M, Stanganelli, I, Talamini, R, Testori, A, Caracò, C, Pasquali, S, Visca, P, Bajetta, E, Bernengo, Mg, Bono, R, Botti, G, Cascinelli, N, Catricala’, C, Chiarugi, A, Clemente, C, Crocetti, E, Fargnoli, Mc, Ferraresi, V, Gandini, S, Ghiorzo, P, Guida, M, Natali, Pg, Parmiani, G, Pizzichetta, Ma, Ridolfi, R, Santinami, M, and Zanovello, P

Subjects
diagnosi, tadiazione, follow-up, Melanoma, stadiazione, terapia
Abstract

"-"

Published
2012

25. MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project

Author

Tagliabue, E, Fargnoli, MC, Gandini, S, Maisonneuve, P, Liu, F, Kayser, M, Nijsten, T, Han, J, Kumar, R, Gruis, NA, Ferrucci, L, Branicki, W, Dwyer, T, Blizzard, L, Helsing, P, Autier, P, Garcia-Borron, JC, Kanetsky, PA, Landi, MT, Little, J, Newton-Bishop, J, Sera, F, Raimondi, S, Tagliabue, E, Fargnoli, MC, Gandini, S, Maisonneuve, P, Liu, F, Kayser, M, Nijsten, T, Han, J, Kumar, R, Gruis, NA, Ferrucci, L, Branicki, W, Dwyer, T, Blizzard, L, Helsing, P, Autier, P, Garcia-Borron, JC, Kanetsky, PA, Landi, MT, Little, J, Newton-Bishop, J, Sera, F, and Raimondi, S

Abstract

BACKGROUND: The melanocortin-1-receptor (MC1R) gene regulates human pigmentation and is highly polymorphic in populations of European origins. The aims of this study were to evaluate the association between MC1R variants and the risk of non-melanoma skin cancer (NMSC), and to investigate whether risk estimates differed by phenotypic characteristics. METHODS: Data on 3527 NMSC cases and 9391 controls were gathered through the M-SKIP Project, an international pooled-analysis on MC1R, skin cancer and phenotypic characteristics. We calculated summary odds ratios (SOR) with random-effect models, and performed stratified analyses. RESULTS: Subjects carrying at least one MC1R variant had an increased risk of NMSC overall, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC): SOR (95%CI) were 1.48 (1.24-1.76), 1.39 (1.15-1.69) and 1.61 (1.35-1.91), respectively. All of the investigated variants showed positive associations with NMSC, with consistent significant results obtained for V60L, D84E, V92M, R151C, R160W, R163Q and D294H: SOR (95%CI) ranged from 1.42 (1.19-1.70) for V60L to 2.66 (1.06-6.65) for D84E variant. In stratified analysis, there was no consistent pattern of association between MC1R and NMSC by skin type, but we consistently observed higher SORs for subjects without red hair. CONCLUSIONS: Our pooled-analysis highlighted a role of MC1R variants in NMSC development and suggested an effect modification by red hair colour phenotype.

Published
2015

26. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy

Author

Fargnoli, Mc, Piccioni, A, Neri, L, Tambone, S, Pellegrini, C, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Piccioni, A, Neri, L, Tambone, S, Pellegrini, C, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Daylight photodynamic therapy (DL-PDT) with methyl aminolevulinate (MAL) is a simplified PDT procedure that was recently shown in a few trials to be effective for grade I actinic keratosis (AK), with improved tolerability and reduced time of clinical attendance as compared to conventional PDT (c-PDT).

Published
2015

27. Topical and systemic medical treatments of basal cell carcinoma

Author

Sollena, P, Del Regno, L, Fargnoli, Mc, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Sollena, P, Del Regno, L, Fargnoli, Mc, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Basal cell carcinoma (BCC) is the most common non melanoma skin cancer (NMSC) in white individuals over the age of 40 years. BCCs usually grow slowly and rarely metastasize, but can be locally invasive if neglected or of an aggressive subtype. The local tissue destruction caused by an untreated BCC can be extensive, therefore optimal treatment should lead to tumour clearance. Surgery and topical medical treatments are successful therapeutic options for most superficial and nodular BCC. Systemic medical treatments may be considered when surgical procedures are not recommended on the basis of the anatomical site and tumor extension, and patients' associated comorbidities. Expected cure rates and cosmetic outcome should be also carefully considered. A better understanding of the molecular mechanisms of BCC pathogenesis can lead to new developing target medical therapies, and data on their efficacy seem encouraging.

Published
2015

28. Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics

Author

Carubbi, F, Chimenti, M, Blasetti, G, Cipriani, P, Musto, A, Fargnoli, Mc, Perricone, R, Giacomelli, R, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Carubbi, F, Chimenti, M, Blasetti, G, Cipriani, P, Musto, A, Fargnoli, Mc, Perricone, R, Giacomelli, R, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

The systemic nature of psoriasis and its association with arthropathy, metabolic syndrome and cardiovascular disease is well established. In contrast, the association between psoriatic disease and other autoimmune disorders is still a matter of debate and data available in the literature are scarce.

Published
2015

29. Photodynamic therapy for basal cell carcinoma

Author

Fargnoli, Mc, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Topical photodynamic therapy is an effective and safe noninvasive treatment for low-risk basal cell carcinoma, with the advantage of an excellent cosmetic outcome. Efficacy of photodynamic therapy in basal cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of photodynamic therapy in the treatment of basal cell carcinoma.

Published
2015

31. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry

Author

Gisondi, P., Cazzaniga, S., Chimenti, S., Giannetti, A., Maccarone, M, Picardo, M., Girolomoni, G., Naldi, L., Griseta, V, Miracapillo, A, Azzini, M, Mocci, L, Michelini, M, Offidani, A, Bernardini, L, Campanati, A, Ricotti, G, Giacchetti, A, Norat, M, Gualco, F, Castelli, A, Cuccia, A, Diana, A, Roncarolo, G, Belli, Ma, Baldassarre, Ma, Santoro, G, Vena, Ga, Lo Console, F, Filotico, R, Mastrandrea, V, Brunetti, B, Musumeci, F, Carrabba, E, Dal Mas, P, Annicchiarico, F, Benvegnù, B, Spaziani, G, Cusano, F, Saletta Iannazzone, S, Galluccio, A, Pezza, M, Marchesi, L, Imberti, G, Reseghetti, A, Barbera, C, Reggiani, M, Lanzoni, A, Patrizi, A, Bardazzi, F, Antonucci, A, De Tommaso, S, Balestri, R, Wallnofer, W, Ingannamorte, F, Calzavara-Pinton, P, Iannazzi, S, Zane, C, Capezzera, R, Bassisi, S, Rossi, Mt, Altamura, V, Vigl, W, Nobile, C, Aste, N, Murgia, S, Mugheddu, C, Scuderi, G, Baglieri, F, Di Dio, C, Cilioni Grilli, E, Mastronardi, C, Agnusdei, Cp, Antrilli, A, Aulisa, L, Raimondo, U, Scotto di Luzio, G, Battarra, Vc, Farro, P, Plaitano, R, Micali, G, Musumeci, Ml, Massimino, D, Li Calzi, M, La Greca, S, Pettinato, M, Sapienza, G, Valenti, G, De Giacomo PF, D'Amico, D, Arcangeli, F, Brunelli, D, Ghetti, E, Tulli, A, Assi, G, Amerio, P, Laria, G, Prestinari, F, Spadafora, S, Coppola, M, Caresana, G, Pezzarossa, E, Domaneschi, E, Felisi, C, Donato, L, Bertero, M, Musso, L, Pa lazzini, S, Bruscino, P, Agozzino, Uc, Ottaviani, M, Simoncini, C, Virgili, A, Osti, F, Fabbri, P, Volpi, W, Caproni, M, Lotti, T, Prignano, F, Buggiani, G, Troiano, M, Fenizi, G, Altobella, A, Amoruso, A, Condello, M, Goffredo, A, Righini, Mg, Alessandrini, F, Satolli, F, Zampetti, M, Bertani, E, Fossati, S, Parodi, A, Burlando, M, Fiorucci, C, Nigro, A, Ghigliotti, G, Massone, L, Moise, Gm, Serrai, M, Cannata, G, Campagnoli, Am, Daly, M, Leporati, C, Peila, R, Filosa, G, Bugatti, L, Nicolini, M, Nazzari, G, Cestari, R, Anastasio, F, Larussa, Fm, Pollice, N, De Francesco, F, Mazzocchetti, G, Peris, K, Fargnoli, Mc, Di Cesare, A, De Angelis, L, Flati, G, Biamonte, As, Quarta, G, Congedo, M, Carcaterra, A, Strippoli, D, Fideli, D, Marsili, F, Celli, M, Ceccarini, M, Bachini, L, D'Oria, M, Schirripa, V, De Filippi, C, Martini, P, Lapucci, E, Mazzatenta, C, Ghilardi, A, Simonacci, M, Bettacchi, A, Gasco, R, Zanca, A, Battistini, S, Dattola, S, Vernaci, R, Postorino, F, Zampieri, Pf, Padovan, C, González Intchaurraga MA, Ladurner, J, Guarneri, B, Cannavò, S, Manfrè, C, Borgia, F, Puglisi Guerra, A, Sedona, P, Cattaneo, A, Carrera, C, Fracchiolla, C, Mozzanica, N, Prezzemolo, L, Menni, S, Lodi, A, Martino, P, Monti, M, Mancini, L, Sacrini, F, Altomare, F, Taglioni, M, Lovati, C, Mercuri, Sr, Schiesari, G, Giannetti, A, Conti, A, Lasagni, C, Greco, M, Ronsini, G, Schianchi, S, Fiorentini, C, Niglietta, S, Maglietta, R, Padalino, C, Crippa, D, Pini, M, Rossi, E, Tosi, D, Armas, M, Ruocco, V, Ayala, F, Balato, N, Gaudiello, F, Cimmino, Gf, Monfrecola, G, Gallo, L, Argenziano, G, Fulgione, E, Berruti, G, Ceparano, I, De Michele, I, Giorgiano, D, Leigheb, G, Deledda, S, Peserico, A, Alaibac, M, Piaserico, S, Schiesari, L, Dan, G, Mattei, I, Oro, E, Aricò, M, Bongiorno, Mr, Angileri, R, Amato, S, Todaro, F, Milioto, M, Bellastro, R, Di Nuzzo, S, De Panfilis, G, Zanni, M, Borroni, G, Cananzi, R, Brazzelli, V, Lisi, P, Stingeni, L, Hansel, K, Pierfelice, V, Donelli, S, Rastelli, D, Gasperini, M, Barachini, P, Cecchi, R, Bartoli, L, Pavesi, M, De Paola, S, Corradin, Mt, Ricciuti, F, Piccirillo, A, Viola, L, Tataranni, M, Mautone, Mg, Lo Scocco, G, Niccoli, Mc, Brunasso Vernetti AM, Gaddoni, G, Resta, F, Casadio, Mc, Arcidiaco, Mc, Luvarà, Mc, Albertini, G, Di Lernia, V, Guareschi, E, Catrani, S, Morri, M, De Simone, C, D'Agostino, M, Agostino, I, Calvieri, S, Cantoresi, F, Richetta, A, Sorgi, P, Carnevale, C, Nicolucci, F, Berardesca, E, Gubinelli, E, Chimenti, S, Talamonti, M, Camplone, G, Cruciani, G, Riccardi, F, Barbati, R, Zumiani, G, Pagani, W, Malagoli, Pg, Pellicano, R, Donadio, D, Di Vito, C, Cottoni, F, Montesu, Ma, Pirodda, C, Addis, G, Marongiu, P, Farris, A, Cacciapuoti, M, Verrini, A, Desirello, G, Gnone, M, Fimiani, M, Pellegrino, M, Castelli, G, Zappalà, L, Sesana, G, Ingordo, V, Vozza, Dg, Di Giuseppe, D, Fasciocco, D, Nespoli, P, Papini, M, Cicoletti, M, Bernengo, Mg, Ortoncelli, M, Bonvicino, A, Capella, G, Doveil, Gc, Forte, M, Peroni, A, Salomone, B, Savoia, P, Pippione, M, Zichichi, L, Frazzitta, M, De Luca, G, Tasin, L, Simonetto, S, Ros, S, Trevisan, G, Patamia, M, Miertusova, S, Patrone, A, Frattasio, A, Piccirillo, F, La Spina, S, Di Gaetano, L, Udine, Marzocchi, V, Motolese, A, Venturi, C, Gai, F, Pasquinucci, S, Bellazzi, Rm, Silvestri, T, Girolomoni, G, Gisondi, P, Veller Fornasa, C, Trevisan, Gp., Gisondi, P, Cazzaniga, S, Chimenti, S, Giannetti, A, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, Monfrecola, Giuseppe, Psocare Study, G. r. o. u. p., P., Gisondi, S., Cazzaniga, S., Chimenti, A., Giannetti, M., Maccarone, M., Picardo, G., Girolimoni, L., Naldi, Trevisan, Giusto, Psocare Study Group: [.., M. Reggiani, A. Lanzoni, A. Patrizi, F. Bardazzi, A. Antonucci, S. De Tommaso, R. Balestri, and ]

Subjects
Adult, Male, arterial hypertension, Adolescent, Antineoplastic Agents, Risk Assessment, Severity of Illness Index, Antibodies, Drug Administration Schedule, Cohort Studies, Dose-Response Relationship, Young Adult, Settore MED/35, Age Distribution, Metabolic Diseases, Monoclonal, metabolic disorders, Humans, Psoriasis, Prospective Studies, Registries, Sex Distribution, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Evidence-Based Medicine, Female, Immunosuppressive Agents, Incidence, Italy, Treatment Outcome, 2708, Infectious Diseases, METABOLIC SYNDROME, psoriasis, metabolic abnormalities, Treatment, therapy, Metabolic abnormalitie, metabolic comorbidities, Metabolic abnormalities, Drug
Abstract

OBJECTIVE: To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. DESIGN: Prospective cohort study. SETTING: Italian public referral centres for psoriasis treatment. PATIENTS: First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. MAIN OUTCOME MEASURE: Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension. RESULTS: Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase levels increased in infliximab-treated patients. The average serum creatinine value increased in cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88). CONCLUSION: Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed.

Published
2013

33. 'From the Aosta Valley to the Sicily it is always melanoma but..' : results of a multicentric Italian study from the GIPMe

Author

Fava, P, Chiarugi, A, Crocetti, E, De Simone, P, Clerico, Mr, Fargnoli, Mc, Filosa, G, Pimpinelli, N, Bottoni, U, Calvieri, S, Calzavara Pinton PG, Cannavo', Serafinella, Cavicchini, S, Colombo, E, Fantini, F, Ferreli, C, Fimiani, M, Lisi, P, Manganoni, Am, Osella Abate, S, Papini, M, Peris, K, Rubegni, P, Salvini, C, Savoia, P, Simonacci, M, Strippoli, D, Zaccagna, A, Astrua, C, Atzori, L, Eibenshutz, L, Fiorani, R, Girgenti, V, Guarneri, Claudio, Lamberti, A, Pertusi, G, Bernengo, Mg, Quaglino, P, and Gruppo Italiano Polidisciplinare sul Melanoma

Subjects
risk factors, clinicopathologic features, Melanoma
Published
2012

34. Vascular patterns in basal cell carcinoma

Author

Micantonio, T, Giulia, A, Altobelli, E, Di Cesare, A, Fidanza, R, Riitano, A, Fargnoli, Mc, and Peris, K

Subjects
Adult, Aged, 80 and over, Male, Skin Neoplasms, Adolescent, Neovascularization, Pathologic, Dermoscopy, Middle Aged, Diagnosis, Differential, Young Adult, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Humans, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Melanoma, Aged, Retrospective Studies
Abstract

Dermoscopy has been proved to increase the diagnostic accuracy of basal cell carcinoma (BCC).To characterize the type and frequency of vascular patterns in superficial and nodular BCCs.We retrospectively analysed the dermoscopic images of 504 histopathologically proven BCCs.The most common vascular pattern was represented by arborizing vessels (306/504; 60.7%), which were significantly more frequent in nodular BCCs (nBCCs) compared with superficial BCCs (sBCCs), and in pigmented sBCCs vs. non-pigmented sBCCs (P0.0001). Short fine telangectasias (SFTs) were found in 33.1% (167/504) of cases and were significantly more frequent in sBCCs compared with nBCCs (P0.0001). Hairpin vessels were detected in 52/504 (10.3%) BCCs. Minor vascular patterns included glomerular vessels (41/504; 8.1%), dotted (21/504; 4.2%), comma vessels (5/504; 1.0%) and polymorphous pattern (9/504; 1.8%).Arborizing vessels are prototypic of nBCCs, whereas SFTs are characteristics of sBCCs. Differential diagnosis with squamous cell carcinoma or melanoma is mandatory when a polymorphous pattern is detected.

Published
2011

35. Project: an international pooled-analysis on melanocortin-1 receptor (MC1R) variants and skin carcinogenesis

Author

123.Gandini S, Fargnoli MC, Maisonneuve P, Kaiser M, Kumar R, Nagore E, Han J, Hansson J, Kanetsky PA, Ghiorzo P, Gruis NA, Dwyer T, de Misa RF, Branicki W, Debniak T, Armstrong BK, Marrett LD, Morling N, Landi MT, Palmieri G, Ribas G, Gruber SB, Stratigos A, Millikan RC, Cornelius L, Motokawa T, Anno S, Helsing P, Culver HA, Begg CB, Wong TH, Rosso S, Gallagher RP, Berwick M, Autier P, García-Borrón JC, Little J, Newton-Bishop J, Sera F, and Raimondi S for the M-SKIP Study Group. The M-SKIP

Published
2011

36. The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns

Author

Suppa, M, Altomare, G, Cannavò, Sp, Capizzi, Rodolfo, Catricalà, C, Colombo, E, Fargnoli, Mc, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, M, Peris, Ketty, Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), Peris, Ketty (ORCID:0000-0002-5237-0463), Suppa, M, Altomare, G, Cannavò, Sp, Capizzi, Rodolfo, Catricalà, C, Colombo, E, Fargnoli, Mc, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, M, Peris, Ketty, Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Melanoma incidence/mortality is increasing worldwide. "Euromelanoma Day" is a pan-European campaign for skin cancer prevention. Results of the 2010 Euromelanoma Day in Italy are reported herein.

Published
2014

37. The first skin cancer screening day at the Italian parliament: a Euromelanoma initiative

Author

Suppa, M, Neri, L, Bianchi, L, Capizzi, Rodolfo, Carbone, A, Catricalà, C, Chimenti, S, Fargnoli, Mc, Fossati, B, Frascione, P, Peris, Ketty, Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), Peris, Ketty (ORCID:0000-0002-5237-0463), Suppa, M, Neri, L, Bianchi, L, Capizzi, Rodolfo, Carbone, A, Catricalà, C, Chimenti, S, Fargnoli, Mc, Fossati, B, Frascione, P, Peris, Ketty, Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

The effort to decrease incidence/mortality of skin cancer should target not only the general public but also politicians and decision makers, to create a proper health policy. We report the results of the first Skin Cancer Screening Day at the Italian Parliament, organized to draw politicians' attention on skin cancer.

Published
2014

38. Skin cancer risk in autoimmune connective tissue diseases

Author

Kostaki, D, Antonini, A, Peris, Ketty, Fargnoli, Mc, Peris, Ketty (ORCID:0000-0002-5237-0463), Kostaki, D, Antonini, A, Peris, Ketty, Fargnoli, Mc, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Cutaneous malignancies have been significantly associated with autoimmune connective tissue diseases (ACTDs). This review focuses on the current state of knowledge on skin cancer risk in the most prevalent ACTDs in dermatology including lupus erythematosus, scleroderma, dermatomyositis and Sjögren syndrome. Potential pathogenetic mechanisms for the association between ACTDs and malignancy involve disease-related impairment of immune system, sustained cutaneous inflammation, drug-associated immune suppression and increased susceptibility to acquired viral infections. An additional causal role might be played by environmental factors such as UV exposure and smoking. The occurrence of skin cancer can have a profound impact on the already compromised quality of life of ACTD patients. Therefore, effective screening and monitoring strategies are essential for ACTD patients as early detection and prompt therapeutic intervention can reduce morbidity and mortality in these patients.

Published
2014

41. Photodynamic therapy for the treatment of micro invasive squamous cell carcinoma of the lower lip: a case report

Author

Fargnoli, Mc, Kostaki, D, Piccioni, A, Di Stefani, Alessandro, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Kostaki, D, Piccioni, A, Di Stefani, Alessandro, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) is approved in Europe for the treatment of actinic keratosis and Bowen's disease, both intraepithelial forms of squamous cell carcinoma (SCC). A therapeutic effect of MAL--PDT has been recently suggested for superficial, microinvasive and well--differentiated cutaneous SCC. We describe the successful use of MAL--PDT in a recently observed patient with microinvasive SCC of the lower lip and review published data on the use of PDT with MAL or --aminolevulinic acid (ALA) in cutaneous microinvasive SCC. A patient with a biopsy--proven recurrent microinvasive SCC of the lower lip was treated with 2 cycles of MAL--PDT. Complete clinical, dermoscopic and histopathological clearance was obtained after 2 cycles of MAL--PDT with an excellent cosmetic result and a sustained remission after 24--month follow--up. A review of the few studies reporting on the use of MAL--PDT or ALA--PDT for cutaneous microinvasive SCCs was carried out. MAL--PDT might represent a non--invasive treatment option for microinvasive SCC of the lower lip if patients are not eligible for surgery. Post--treatment histopathological confirmation and a long--term follow--up are strictly recommended.

Published
2014

42. Treatments of advanced basal cell carcinoma: a review of the literature

Author

Peris, Ketty, Tambone, S, Kostaki, D, Varrassi, E, Fargnoli, Mc, Peris, Ketty (ORCID:0000-0002-5237-0463), Peris, Ketty, Tambone, S, Kostaki, D, Varrassi, E, Fargnoli, Mc, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Advanced basal cell carcinoma (aBCC) encompasses locally advanced BCC (laBCC) and metastatic BCC (mBCC), two variants of BCC with a limited prevalence worldwide. Treatment of aBCC is still very challenging for the lack of randomized controlled trials/guidelines and the scarcity of available therapeutic options. Based on current data, surgical procedures and radiotherapy are considered the treatments of choice for aBCC although often associated with substantial morbidity and/or deformity. Alternatively, systemic chemotherapy and electrochemotherapy can be used but standardized treatment schedules and randomized clinical trials are not available for both treatments. In recent years, novel tumor--specific and pathogenesis--based molecules have been developed for the treatment of aBCC. A number of clinical trials have recently demonstrated the efficacy and tolerability of vismodegib, the first novel systemic, anti--Smo target cancer therapy for aBCC. Additional molecules currently investigated in phase I--III clinical trials include other Smo antagonists and itraconazole. The contribution of a multidisciplinary team composed of dermatologists, surgeons, oncologists, pathologists, radiologists and radiotherapists is required to deal with the spectrum of issues that emerge from managing patients affected by aBCC.

Published
2014

43. Melanoma detection in Italian pigmented lesion clinics

Author

Argenziano, G, Moscarella, E, Annetta, A, Battarra, Vc, Brunetti, B, Buligan, C, Cantisani, C, Capizzi, Rodolfo, Carbone, A, Carlino, A, Corsetti, V, Damiano, A, De Salvo, V, De Simone, P, Di Caterino, P, Fargnoli, Mc, Ferrari, A, Fossati, Barbara, Frascione, P, Ghigliotti, G, González Inchaurraga, Ma, Guerriero, Cristina, Landi, C, Mazzoni, L, Mirizzi, S, Palazzo, G, Pedretti, A, Peris, Ketty, Piemonte, P, Rossi, A, Satta, R, Savoia, F, Scalvenzi, M, Stanganelli, I, Stinco, G, Zampieri, P, Zalaudek, I., Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), Peris, Ketty (ORCID:0000-0002-5237-0463), Argenziano, G, Moscarella, E, Annetta, A, Battarra, Vc, Brunetti, B, Buligan, C, Cantisani, C, Capizzi, Rodolfo, Carbone, A, Carlino, A, Corsetti, V, Damiano, A, De Salvo, V, De Simone, P, Di Caterino, P, Fargnoli, Mc, Ferrari, A, Fossati, Barbara, Frascione, P, Ghigliotti, G, González Inchaurraga, Ma, Guerriero, Cristina, Landi, C, Mazzoni, L, Mirizzi, S, Palazzo, G, Pedretti, A, Peris, Ketty, Piemonte, P, Rossi, A, Satta, R, Savoia, F, Scalvenzi, M, Stanganelli, I, Stinco, G, Zampieri, P, Zalaudek, I., Capizzi, Rodolfo (ORCID:0000-0001-6149-9237), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Accuracy in melanoma detection is important to recognize early curable melanomas and to minimize the unnecessary excision of benign lesions. The aim of this paper was to evaluate melanoma screening accuracy of Italian pigmented lesion clinics in terms of number needed to excise (NNE), melanoma thickness, and number of melanomas diagnosed during patient follow-up.

Published
2014

44. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

Author

Shi, J, Yang, Xr, Ballew, B, Rotunno, M, Calista, D, Fargnoli, Mc, Ghiorzo, P, Bressac De Paillerets, B, Nagore, E, Avril, Mf, Caporaso, Ne, Mcmaster, Ml, Cullen, M, Wang, Z, Zhang, X, Bruno, W, Pastorino, L, Queirolo, P, Banuls Roca, J, Garcia Casado, Z, Vaysse, A, Mohamdi, H, Riazalhosseini, Y, Foglio, M, Jouenne, F, Hua, X, Hyland, Pl, Yin, J, Vallabhaneni, H, Chai, W, Minghetti, P, Pellegrini, C, Ravichandran, S, Eggermont, A, Lathrop, M, Peris, Ketty, Scarra, Gb, Landi, G, Savage, Sa, Sampson, Jn, He, J, Yeager, M, Goldin, Lr, Demenais, F, Chanock, Sj, Tucker, Ma, Goldstein, Am, Liu, Y, Landi, Mt, Peris, Ketty (ORCID:0000-0002-5237-0463), Shi, J, Yang, Xr, Ballew, B, Rotunno, M, Calista, D, Fargnoli, Mc, Ghiorzo, P, Bressac De Paillerets, B, Nagore, E, Avril, Mf, Caporaso, Ne, Mcmaster, Ml, Cullen, M, Wang, Z, Zhang, X, Bruno, W, Pastorino, L, Queirolo, P, Banuls Roca, J, Garcia Casado, Z, Vaysse, A, Mohamdi, H, Riazalhosseini, Y, Foglio, M, Jouenne, F, Hua, X, Hyland, Pl, Yin, J, Vallabhaneni, H, Chai, W, Minghetti, P, Pellegrini, C, Ravichandran, S, Eggermont, A, Lathrop, M, Peris, Ketty, Scarra, Gb, Landi, G, Savage, Sa, Sampson, Jn, He, J, Yeager, M, Goldin, Lr, Demenais, F, Chanock, Sj, Tucker, Ma, Goldstein, Am, Liu, Y, Landi, Mt, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Although CDKN2A is the most frequent high-risk melanoma susceptibility gene, the underlying genetic factors for most melanoma-prone families remain unknown. Using whole-exome sequencing, we identified a rare variant that arose as a founder mutation in the telomere shelterin gene POT1 (chromosome 7, g.124493086C>T; p.Ser270Asn) in five unrelated melanoma-prone families from Romagna, Italy. Carriers of this variant had increased telomere lengths and numbers of fragile telomeres, suggesting that this variant perturbs telomere maintenance. Two additional rare POT1 variants were identified in all cases sequenced in two separate Italian families, one variant per family, yielding a frequency for POT1 variants comparable to that for CDKN2A mutations in this population. These variants were not found in public databases or in 2,038 genotyped Italian controls. We also identified two rare recurrent POT1 variants in US and French familial melanoma cases. Our findings suggest that POT1 is a major susceptibility gene for familial melanoma in several populations.

Published
2014

45. Selective sunscreen application on nevi: frequency and determinants of a wrong sun-protective behaviour

Author

Suppa, M, Argenziano, G, Moscarella, E, Hofmann Wellenhof, R, Thomas, L, Catricalà, C, Gutiérrez González, E, Fargnoli, Mc, Peris, Ketty, Zalaudek, I., Peris, Ketty (ORCID:0000-0002-5237-0463), Suppa, M, Argenziano, G, Moscarella, E, Hofmann Wellenhof, R, Thomas, L, Catricalà, C, Gutiérrez González, E, Fargnoli, Mc, Peris, Ketty, Zalaudek, I., and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Sunscreen use is generally recommended in order to prevent skin cancer but erroneous patterns of use were reported, including the selective application on melanocytic nevi.

Published
2014

46. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families

Author

Liang, X, Pfeiffer, Rm, Li, W, Brossard, M, Burke, L, Wheeler, W, Calista, D, Fargnoli, Mc, Ghiorzo, P, Peris, Ketty, Bianchi Scarra, G, Chaudru, V, Zelenika, D, Maeder, D, Burdette, L, Yeager, M, Chanock, S, Landi, Mt, Demenais, F, Tucker, Ma, Goldstein, Am, Yang, Xr, Peris, Ketty (ORCID:0000-0002-5237-0463), Liang, X, Pfeiffer, Rm, Li, W, Brossard, M, Burke, L, Wheeler, W, Calista, D, Fargnoli, Mc, Ghiorzo, P, Peris, Ketty, Bianchi Scarra, G, Chaudru, V, Zelenika, D, Maeder, D, Burdette, L, Yeager, M, Chanock, S, Landi, Mt, Demenais, F, Tucker, Ma, Goldstein, Am, Yang, Xr, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Dysplastic nevi (DN) is a strong risk factor for cutaneous malignant melanoma (CMM), and it frequently occurs in melanoma-prone families. To identify genetic variants for DN, we genotyped 677 tagSNPs in 38 melanoma candidate genes that are involved in pigmentation, DNA repair, cell cycle control, and melanocyte proliferation pathways in a total of 504 individuals (310 with DN, 194 without DN) from 53 melanoma-prone families (23 CDKN2A mutation positive and 30 negative). Conditional logistic regression, conditioning on families, was used to estimate the association between DN and each single-nucleotide polymorphism (SNP) separately, adjusted for age, sex, CMM, and CDKN2A status. P-values for SNPs in the same gene were combined to yield gene-specific P-values. Two genes, CDK6 (cyclin-dependent kinase 6) and XRCC1, were significantly associated with DN after Bonferroni correction for multiple testing (P=0.0001 and 0.00025, respectively), whereas neither gene was significantly associated with CMM. Associations for CDK6 SNPs were stronger in CDKN2A mutation-positive families (rs2079147, Pinteraction=0.0033), whereas XRCC1 SNPs had similar effects in mutation-positive and -negative families. The association for one of the associated SNPs in XRCC1 (rs25487) was replicated in two independent data sets (random-effect meta-analysis: P<0.0001). Our findings suggest that some genetic variants may contribute to DN risk independently of their association with CMM in melanoma-prone families.

Published
2014

47. Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence

Author

Fargnoli, Mc, Suppa, M, Micantonio, T, Antonini, A, Tambone, S, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Suppa, M, Micantonio, T, Antonini, A, Tambone, S, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

The dermoscopic features of acral acquired melanocytic naevi have been extensively reported in the adult population. Little knowledge is available on acral naevi in childhood and adolescence.

Published
2014

48. Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype

Author

Fargnoli, Mc, Sera, F, Suppa, M, Piccolo, D, Landi, Mt, Chiarugi, A, Pellegrini, C, Seidenari, S, Peris, Ketty, Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Sera, F, Suppa, M, Piccolo, D, Landi, Mt, Chiarugi, A, Pellegrini, C, Seidenari, S, Peris, Ketty, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Several algorithms are available for the dermoscopic diagnosis of pigmented skin lesions. The MC1R gene is a key determinant of pigmentation characteristics that are established host-related melanoma risk factors.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results